Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T19:17:22.130Z.
Calculation as of: 2026-10-06T19:17:22.130Z.
Quote observation: 2026-10-06T19:15:25.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e0aae41c25609cbe98cd8c59fbdc20e812e1ea61d6a67e0b8df2c56749153647
PE RATIO
N/A
Market Cap
$376.44M
PE Ratio
N/A
TTM Avg
4952.81
3Y Avg
4952.81
5Y Avg
4952.81
Market Cap
$374.62M
PE Ratio
N/A
TTM Avg
20.42
3Y Avg
20.42
5Y Avg
20.42
Market Cap
$360.40M
PE Ratio
N/A
TTM Avg
170.63
3Y Avg
170.63
5Y Avg
170.63
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | $376.32M | N/A | N/A | N/A | N/A |
| Canopy Growth Corporation (CGC)vs › | $376.44M | N/A | 4952.81 | 4952.81 | 4952.81 |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $374.62M | N/A | 20.42 | 20.42 | 20.42 |
| YD Bio Limited Ordinary Shares (YDES)vs › | $378.24M | N/A | N/A | N/A | N/A |
| Orthofix Medical Inc. (OFIX)vs › | $381.58M | N/A | 157.27 | 122.07 | 183.95 |
| Zura Bio Limited (ZURA)vs › | $383.32M | N/A | N/A | N/A | N/A |
| Opus Genetics, Inc. (IRD)vs › | $364.85M | N/A | N/A | N/A | N/A |
| REGENXBIO Inc. (RGNX)vs › | $389.80M | N/A | 13.34 | 13.34 | 21.63 |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $360.40M | N/A | 170.63 | 170.63 | 170.63 |
| Embecta Corp. (EMBC)vs › | $355.08M | 4.04 | 4.83 | 10.37 | 9.91 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$6.19
Forward EPS (Est.)
$-2.76
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
